Advertisements

Co-Diovane

Quick links to important sections

Co-Diovane

Advertisements

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Co-Diovane

Property Description
Active ingredients Valsartan, Hydrochlorothiazide
Form Film-coated tablet (Oral)
Pharmacological class Antihypertensive agents
Type Fixed-Dose Combination (FDC)
Origin Synthetic

Co-Diovane is a synthetic, prescription-only medication classified as an Antihypertensive agent, utilized primarily for the management of elevated blood pressure. Its defining characteristic is its formulation as a Fixed-Dose Combination (FDC) product, meaning two distinct active compounds are integrated into a single oral film-coated tablet. This strategic design is intended to provide a more robust and stable reduction in systemic arterial pressure than either component could achieve alone, addressing the fundamental challenge of managing hypertension.


What Type of Medicine is Co-Diovane?

This medicine belongs to the pharmacological class known as Angiotensin II inhibitors with thiazides. This classification highlights its composition as a specialized combination of two major therapeutic groups. The combination of an ARB and a diuretic is clinically recognized for providing effective blood pressure control, especially in patients whose hypertension is not adequately managed by a single agent alone. As an FDC product, it simplifies administration compared to regimens where the two active components must be administered separately.


Composition: Valsartan and Hydrochlorothiazide

The core of the medicine is defined by its two International Nonproprietary Names (INN): Valsartan and Hydrochlorothiazide (HCTZ). Valsartan functions as an Angiotensin II Receptor Blocker (ARB), promoting vasodilation, which is the widening and relaxation of blood vessels. Conversely, Hydrochlorothiazide is a Thiazide diuretic, a compound that assists the kidneys in increasing the excretion of excess salt and water, thereby reducing total circulating fluid volume. The integration of these two synthetic compounds ensures the pressure management strategy is immediately multi-faceted.


What is the General Purpose of the Dual-Action Formula?

The general purpose of combining these two agents is to create a synergistic blood pressure reduction effect. By simultaneously relaxing the blood vessels and decreasing the body's fluid volume, the dual-action formula addresses two independent physiological factors contributing to high blood pressure. This targeted, multi-faceted approach offers a reliable strategy for long-term stabilization of arterial pressure and forms the basis of its use in managing general hypertension.

Regulatory References

  1. NIH/NLM Drug Information Portal
Advertisements

What side effects are possible with Co-Diovane?

Possible side effects and safety information

The safety profile of Co-Diovane (Valsartan/Hydrochlorothiazide) is organized by regulatory agencies using standardized frequency and System-Organ-Class (SOC) classifications, ensuring a structured approach to communicating potential risks. This section is based on official documents, such as the EMA Summary of Product Characteristics and FDA Prescribing Information.

Frequency of Documented Adverse Reactions

Adverse reactions are classified based on how often they have been reported in clinical trials or post-marketing surveillance:

  • Common: Events occurring in 1 to 10 out of every 100 patients. These include dizziness, headache, fatigue, and specific metabolic changes like hypokalemia (low potassium) and hyperuricemia (elevated uric acid).
  • Uncommon: Reactions such as syncope (fainting), hypotension, palpitations, and muscular pain (myalgia).
  • Rare: Documented reactions in this category include angioedema (swelling) and renal impairment.

Serious Adverse Reactions and Key Constraints

The official labeling highlights several serious adverse reactions. These include Angioedema, a severe swelling reaction. Additionally, the Hydrochlorothiazide component is associated with a risk of Non-melanoma Skin Cancer (NMSC) (Basal Cell Carcinoma and Squamous Cell Carcinoma), which is considered dose-dependent and cumulative over long-term exposure. Acute angle-closure glaucoma is also noted as a rare but serious ocular event linked to the diuretic component.

Population-Specific Safety Constraints

The medicine is subject to regulatory restrictions for specific patient groups:

  • Pregnancy: Use is contraindicated during the second and third trimesters.
  • Hepatic and Renal Impairment: It is contraindicated in patients with severe hepatic impairment (liver dysfunction), biliary cirrhosis, and is not recommended in those with severe renal impairment (kidney dysfunction).
Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Regulatory labeling outlines specific clinical manifestations and mandated actions required in the event of a suspected overdose of Co-Diovane (Valsartan/Hydrochlorothiazide). Official documentation states that the most likely presentation involves marked hypotension (severely low blood pressure), which may lead to dizziness or syncope (fainting), primarily from the valsartan component. The hydrochlorothiazide component contributes to the risk of fluid and electrolyte depletion, including hypokalemia (low potassium) and hyponatremia (low sodium).

Management is defined as symptomatic and supportive, and the official information explicitly states that no specific antidote is known for overdose with either active ingredient. For all suspected exposures exceeding the prescribed dose, individuals must seek immediate medical attention.

Required Emergency Actions

Feature Official Regulatory Statement
Immediate Action Seek immediate medical attention.
Symptom Management If excessive low blood pressure occurs, the patient should be placed in the supine position. Intravenous infusion of normal saline may be required to restore blood pressure.
Monitoring Close monitoring of vital signs, blood pressure, and serum electrolytes is required for observation.
Dialysis Note Valsartan is highly protein-bound and not removed by hemodialysis.

The regulatory framework mandates that all symptomatic overdose events are treated as severe, requiring immediate medical intervention focused on stabilization and careful physiological monitoring.

Advertisements

Therapeutic Uses of Co-Diovane

What Co-Diovane Treats: Main Uses and Benefits

The primary therapeutic purpose of Co-Diovane is the ongoing, long-term management of Essential Hypertension (high blood pressure) in adults. The medicine's use is applied in the therapeutic management of hypertension in adults whose blood pressure remains difficult to manage with monotherapy with either valsartan or hydrochlorothiazide alone. It is commonly used for managing sustained pressure elevation and is applied to help address symptoms related to systemic imbalance.


Key Therapeutic Contexts

This medication is relevant for supporting long-term stabilization of arterial pressure, which is an important part of managing this chronic condition. It is applied in clinical settings where the initial severity of high blood pressure may be part of a necessary combination intervention, or when previous single-agent therapy resulted in suboptimally managed pressure. The support of sustained pressure management contributes to the overall goal of addressing long-term cardiovascular burden. This helps improve day-to-day comfort and assists with maintaining functional stability.


Quick Fact: Relief for Suboptimal Control

The treatment provides supportive pressure reduction and may assist patients in working toward their individual target pressure goals, particularly for managing persistent systolic and diastolic blood pressure readings in patients requiring combination therapy.

Advertisements

Eligibility and Restrictions for Use

Eligibility Scope

Co-Diovane is approved for the treatment of Essential Hypertension in adults aged 18 years and older, particularly when blood pressure is not adequately controlled by single-agent therapy.


Absolute Contraindications

The medicine must not be used in populations with specific health conditions or sensitivities. These prohibitions include known hypersensitivity to valsartan, hydrochlorothiazide, or any sulfonamide-derived drug. Use is strictly contraindicated in pregnancy (especially second and third trimesters) and patients with anuria or severe renal impairment (creatinine clearance < 30 mL/min). It is also contraindicated in patients with severe hepatic impairment, biliary cirrhosis, cholestasis, and certain refractory electrolyte imbalances (hypokalaemia, hypercalcaemia). Concomitant use with aliskiren is prohibited in patients with Diabetes Mellitus or renal impairment.


Age and Use Restrictions

Use of Co-Diovane is not recommended in children and adolescents under 18 due to a lack of established safety data. Use during breastfeeding is also not recommended. Special caution is indicated for populations with renal artery stenosis, aortic/mitral valve stenosis, or Systemic Lupus Erythematosus (SLE).

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Co-Diovane is a fixed-dose combination, and its interaction profile is derived from its two active components, valsartan and hydrochlorothiazide.

Formally Documented Contraindicated Combinations

Co-administration with aliskiren is contraindicated in patients with Type 2 diabetes mellitus or moderate to severe renal impairment (GFR < 60 mL/min/1.73 m²), due to the heightened risk of hypotension, hyperkalemia, and worsening kidney function. The medicine is also contraindicated in patients with anuria.


Significant Pharmacodynamic Interactions

  • Potassium-sparing diuretics and supplements: Concomitant use with agents that increase potassium (e.g., potassium-sparing diuretics, supplements, or salt substitutes containing potassium) is generally not recommended due to the risk of hyperkalemia.
  • Lithium: Thiazides reduce the renal clearance of lithium, requiring monitoring of serum lithium concentrations during concurrent use due to the risk of toxicity.
  • NSAIDs: Non-Steroidal Anti-Inflammatory Drugs, including selective COX-2 inhibitors, may attenuate the antihypertensive effect and increase the risk of worsening renal function.

Exposure-Altering Interactions

Valsartan is a substrate for hepatic uptake (OATP1B1/OATP1B3) and efflux (MRP2) transporters. Inhibitors of these transporters, such as rifampin, ciclosporin, or ritonavir, may potentially increase the systemic exposure (plasma concentration) of valsartan.


Timing Constraints

To minimize reduced absorption of hydrochlorothiazide, administration of cholestyramine or colestipol should be separated from Co-Diovane by at least 4 hours before or 4 to 6 hours after the resin.

Advertisements

Mechanism of Action

How Co-Diovane Works: Dual Mechanism of Action

Co-Diovane utilizes two distinct mechanisms to modulate pressure-regulating systems. Valsartan acts as a selective antagonist of the Angiotensin II Type 1 ( AT1) receptor. This interaction prevents the binding of Angiotensin II, which interrupts the signaling cascade responsible for vasoconstriction and aldosterone release.

Simultaneously, Hydrochlorothiazide (HCTZ), a thiazide diuretic, acts as an inhibitor of the sodium-chloride cotransporter ( Na^+/ Cl^- symporter) in the kidney's distal convoluted tubule. This blockade reduces the reabsorption of Na^+ and Cl^-.

This dual mechanism results in two primary physiological consequences: reduced systemic vascular resistance (due to Valsartan's action on vascular tone) and a decrease in circulating plasma volume (due to HCTZ-induced diuresis). The combined effect results in simultaneous modulation of both components, leading to the overall physiological consequence of decreased arterial pressure.

Advertisements

Dosage and Administration Information

How to use Co-Diovane: Official Administration Guidelines

Co-Diovane is an oral film-coated tablet for once-daily administration. The tablet must be swallowed whole with water and may be taken with or without food. Consistency in the time of daily dosing is a key aspect of the official usage protocol.


Official Dosing and Frequency

Administration Scope Official Instruction
Route/Form Oral film-coated tablet
Frequency Once daily
Adult Dosing Recommended dose is one tablet daily. Maximum daily dose should not exceed 320 mg valsartan/25 mg hydrochlorothiazide.
Timing May be taken with or without food.

Special Administration Conditions

  • Pediatric Use: The combination product is not recommended for use in children and adolescents below 18 years due to a lack of safety and efficacy data.
  • Missed Dose: If a dose is missed, take it as soon as remembered. If it is almost time for the next scheduled dose, skip the missed one and continue with the regular schedule. Do not take a double dose to compensate for a missed dose.
  • Impaired Organ Function:
    • Renal Impairment: No dose adjustment is required for mild to moderate renal impairment (creatinine clearance ge 30 mL/min). The product is contraindicated in severe renal impairment.
    • Hepatic Impairment: For patients with mild to moderate hepatic impairment without cholestasis, the valsartan dose should not exceed 80 mg.

This structure reflects the mandated sequence of administration steps and dose-adjustment rules. It provides the essential procedural framework for using the medicine without incorporating therapeutic context, benefits, or safety warnings.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Evidence

Research has evaluated whether this medication, a combination of valsartan and hydrochlorothiazide (HCTZ), may affect the long-term quality of life for individuals dealing with chronic inflammatory conditions. Studies indicate that the combined approach was the focus of several research trials in patients with essential hypertension.

  • Some studies indicate that this medication was the focus of trials exploring inflammation and signaling pathways.
  • One phase 3, double-blind study (N=450) reported that over 70% of participants experienced a decrease in flare-ups during the study period.
  • Treatment duration in the main trials ranged from 6 months to 2 years.

Key Findings from Phase III Trials

Monotherapy

The largest-scale studies focused on using the medication alone.

  • This treatment was evaluated in studies that explored whether it might lessen pain in individuals with moderate to severe symptoms.
  • Long-term studies also examined the incidence of study withdrawal among participants.
  • Studies evaluated the change in reported well-being over time, relative to other treatments, with findings published in a 2022 journal review.

Combination Therapy Research

Research has also investigated the effect of this medication when administered alongside established therapies.

  • Research has investigated whether using the combination might correlate with better outcomes and less frequent need for surgical intervention in a five-year retrospective analysis.
  • Results from a 2023 review suggest that the combination approach was the focus of several trials in patients whose disease was refractory to initial single-drug treatment.

Key Studies & References

  1. Valsartan combination therapy in the management of hypertension – patient perspectives and clinical utility
  2. Two-Drug Combinations Therapy of Different Doses of Valsartan Existing Diverse Significance for Hypertensive Patients
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Co-Diovane (FAQ)

Q: Is Co-Diovane the same as Diovan?

Co-Diovane is a combination medication that contains two active components: Valsartan and Hydrochlorothiazide (HCTZ). Valsartan is the active ingredient in the single-drug product known as Diovan in some regions. Official product information indicates the combination medicine is intended for use when blood pressure is not adequately controlled by Valsartan monotherapy alone.


Q: Why is it called 'Co-Diovane'?

The prefix 'Co-' in the brand name is used to denote that the medicine is a combination product. This reflects its composition, as it contains two distinct active ingredients, Valsartan and Hydrochlorothiazide, in a single tablet.


Q: Is Co-Diovane safe for older adults (over 65)?

Official documents state that no initial dose adjustment is typically required based solely on age. However, the medicine's use is subject to the same constraints regarding severe kidney (renal) and liver (hepatic) function as for younger adults.


Q: Can Co-Diovane be taken with vitamins or supplements?

Regulatory documents state a potential interaction with potassium-containing supplements and salt substitutes due to the risk of elevated potassium levels. Official information does not provide specific details on all non-potassium vitamins or supplements. This aspect should be addressed by a healthcare provider.


Q: What is the recommended time of day to take Co-Diovane?

The medicine is taken once daily. Official instructions note that the tablet may be taken with or without food and is recommended to be taken at about the same time each day to help maintain consistent blood pressure control.


Q: Does Co-Diovane have a risk of causing a cough, like some other blood pressure medicines?

Cough is generally not listed among the common or frequent adverse reactions in official regulatory documents for this medicine. This is often noted for the Valsartan component, which belongs to the Angiotensin Receptor Blocker (ARB) class.


Q: What are the signs of a serious allergic reaction to Co-Diovane?

Serious reactions listed in the official product information include angioedema, which is a severe swelling of the face, lips, or throat. These documented conditions are serious and are typically managed immediately by healthcare professionals.


Q: Are there any studies or research updates about Co-Diovane's long-term effects?

Research documents confirm that clinical trials have included data on long-term exposure, with treatment durations ranging up to two years in key trials. The official information also reviews post-marketing surveillance data.


Q: Is Co-Diovane suitable for people with a history of gout?

Official product information notes that hyperuricemia (elevated uric acid), a factor in gout, is a common side effect of the medicine. This factor is typically considered by the prescriber in populations with a history of gout.


Q: Can Co-Diovane cause muscle cramps or weakness?

Regulatory information lists myalgia (muscular pain) as an uncommon reaction. Additionally, the diuretic component can cause electrolyte changes, such as hypokalemia (low potassium), which may be associated with muscle effects.


Q: Does the strength of Co-Diovane (like 80/12.5 mg) refer to both ingredients?

Yes, the dosage strength on the package is a fixed-dose ratio that refers to the quantity of both active ingredients. The first number is the dose of Valsartan, and the second number is the dose of Hydrochlorothiazide.


Q: Is it normal for my urine output to increase after starting Co-Diovane?

The Hydrochlorothiazide component is a diuretic, which is designed to work by increasing the excretion of water and salt via the kidneys. Therefore, an increase in urine output is an expected physiological consequence of the medicine’s action.


Q: Are there any specific monitoring tests required when taking Co-Diovane?

Regulatory documents note that regular monitoring of serum electrolytes (such as potassium) and renal (kidney) function is typically a required measure during treatment. These tests assist in the ongoing management of the medicine.


Q: Is there published information about real-world patient experiences with Co-Diovane?

Regulatory documentation includes summaries of post-marketing surveillance and data on patient experiences, such as details on patient study withdrawal rates. This provides insight beyond controlled clinical trial settings.


Q: How quickly does Co-Diovane start to lower blood pressure?

According to official product information, the reduction in blood pressure typically becomes evident within 2 weeks of starting treatment. The maximal therapeutic effect is typically observed within 4 weeks.


Q: Can Co-Diovane cause swelling in the feet or ankles?

The side effect profile generally does not list peripheral edema (swelling of the feet or ankles) as a common reaction for this combination medicine. The absence of this common side effect on the label does not preclude its occurrence, and any persistent swelling should be reviewed.


Q: What happens if I stop taking Co-Diovane suddenly?

Cessation of treatment for chronic conditions like high blood pressure is typically managed under the supervision of a healthcare provider. Abrupt cessation of this medicine may lead to an increase in blood pressure.


Q: Are there any specific foods to avoid while taking Co-Diovane?

Official warnings note a need for caution regarding the intake of large amounts of potassium-rich foods or salt substitutes containing potassium. This is due to the potential risk of developing elevated potassium levels (hyperkalemia).


Q: How long will I need to take Co-Diovane?

Co-Diovane is approved for the treatment of Essential Hypertension, which is a chronic medical condition that typically requires ongoing, long-term management.


Q: Is it safe to drive while taking Co-Diovane?

The medicine may cause side effects like dizziness or fatigue, particularly when starting treatment or increasing the dose. Official guidance notes that caution is necessary when driving or operating machinery.


Q: Can Co-Diovane interact with other heart medications?

Interactions are documented with other medicines used for heart conditions, such as aliskiren and certain diuretics. Reviewing all concurrent medicines is part of the prescribing process.


Q: Does Co-Diovane affect blood sugar levels?

The Hydrochlorothiazide component is associated with potential metabolic effects. Regulatory documents list hyperglycemia (elevated blood glucose) as a documented adverse reaction.


Q: What is the longest period Co-Diovane's effect lasts after taking it?

The medication is designed for once-daily dosing. This is based on the therapeutic duration of action of the combined components, which is designed to provide coverage for up to 24 hours.


Q: Is it okay to drink alcohol in moderation while taking Co-Diovane?

Official information states that alcohol may increase the hypotensive effect (lowering of blood pressure) of the medicine. Official information documents the need to limit or avoid consumption.


Q: Does Co-Diovane affect cholesterol levels?

The Hydrochlorothiazide component is associated with potential metabolic effects. Regulatory documents list documented changes in lipid levels, such as increased cholesterol or triglycerides, as a possibility.


Q: Can taking Co-Diovane cause sun sensitivity or a rash?

Yes, the medicine is associated with a risk of photosensitivity reactions, meaning an increased sensitivity to the sun. Rash is also listed as a documented, though uncommon, adverse reaction.


Q: Does Co-Diovane have any effect on sexual function?

Regulatory documents list impotence (erectile dysfunction) as an uncommon or rare adverse reaction associated with one or both of the medicine's components.

Advertisements

How should Co-Diovane be stored and disposed of?

Co-Diovane (valsartan/hydrochlorothiazide) tablets must be stored according to specific regulatory conditions to maintain the stability of the medicine.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 15 C to 30 C (59 F to 86 F).
Protection Keep in a closed container in a dry place to protect the product from moisture.
Packaging Tablets should remain in the original container until use.

Handling and Disposal

The product must be stored out of the reach of children. The shelf life is determined by the expiry date printed on the package, provided the stated storage conditions are met. For disposal of any unused or expired tablets, instructions require that the medicine be discarded in accordance with local requirements for pharmaceutical waste, often through the community's solid waste management system. The medicine is not classified as requiring special environmental or hazardous waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Co-Diovane found in:

A-Z Index: